NEW YORK, Oct. 9 – LifeSpan BioSciences of Seattle said Tuesday it had signed Aventis Pharma as its sixth subscriber to its G protein-coupled receptors database.
The database Lifespan will provide to Aventis of Strasbourg, France, includes information on non-olfactory GPCRs. The database, which is designed to help users to identify and prioritize potential drug targets, was designed to be used by Aventis’ branches in the US, Germany, and France.
"We are now mapping the top 320 GPCRs of potential therapeutic interest,” Joseph Brown, CEO of LifeSpan BioSciences, said in a statement.
GPCRs comprise a family of cell-surface molecules that act as receptors for many biologically active compounds and pharmaceuticals.
LifeSpan’s other subscribers are Pfizer, Merck, Bristol-Myers Squibb, Novartis Research Foundation, and Sanofi-Snythelabo.
Financial terms of the deal were not disclosed.